Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

Aiforia Technologies

1.78 EUR

+7.77 %

2,186 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+7.77 %
-1.33 %
-24.43 %
-28.67 %
-34.22 %
-50.67 %
-56.79 %
-
-64.90 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
59.84M EUR
Turnover
89.98K EUR
P/E (adj.) (26e)
-7.17
EV/EBIT (adj.) (26e)
-7.41
P/B (26e)
4.43
EV/S (26e)
13.23
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
08.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.5
2026

Extraordinary general meeting '26

28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release2 hours ago

Aiforia Technologies Plc: Resolutions of the constitutive meeting of the Board of Directors

Aiforia Technologies
Press release7 hours ago

Aiforia has been selected as an AI partner for the PROSTIA project - expands to five new hospitals in Paris

Aiforia Technologies
Regulatory press releaseyesterday

Notice of Aiforia Technologies Plc’s Extraordinary General Meeting 2026

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/8/2026, 12:15 PM

Aiforia Technologies Plc – Managers’ Transactions – Antti Ojala

Aiforia Technologies
Regulatory press release4/2/2026, 12:05 PM

Resolutions of Aiforia Technologies Plc’s Annual General Meeting 2026

Aiforia Technologies
Regulatory press release4/1/2026, 6:20 AM

Aiforia Technologies Plc – Managers’ Transactions – Pekka Mattila

Aiforia Technologies
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Aiforia secures another CE-IVD mark
Analyst Comment3/18/2026, 6:41 AM by
Antti Siltanen

Aiforia secures another CE-IVD mark

The new solution strengthens the product portfolio and supports our growth forecast.

Aiforia Technologies
Press release3/17/2026, 7:30 AM

Aiforia announces the next generation of its CE-IVD marked Prostate Cancer Biopsy AI solution

Aiforia Technologies
Regulatory press release3/16/2026, 3:00 PM

Aiforia Technologies Plc – Managers’ Transactions – Panu Kauppila

Aiforia Technologies
Aiforia H2’25: Green shoots on the clinical side9:39
Video3/16/2026, 9:29 AM by
Antti Siltanen, Isa Hudd

Aiforia H2’25: Green shoots on the clinical side

Aiforia’s H2 revenue growth originated in Europe, where the company has successfully promoted the adoption of clinical models.

Aiforia Technologies
Regulatory press release3/12/2026, 11:00 AM

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release3/11/2026, 2:15 PM

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Regulatory press release3/11/2026, 2:00 PM

Aiforia Technologies Plc Publishes its Board of Directors’ Report and Financial Statements for 2025

Aiforia Technologies
New partnership for Aiforia
Analyst Comment3/11/2026, 6:49 AM by
Antti Siltanen

New partnership for Aiforia

The partnership brings Aiforia's AI applications to a platform already used by pathologists.

Aiforia Technologies
Press release3/10/2026, 8:00 AM

Aiforia and Proscia partner to accelerate AI-driven digital pathology

Aiforia Technologies
Regulatory press release3/10/2026, 7:00 AM

Notice of Aiforia Technologies Plc’s Annual General Meeting 2026

Aiforia Technologies
Aiforia H2'25: Green shoots on the clinical side
Research3/9/2026, 8:51 AM by
Antti Siltanen

Aiforia H2'25: Green shoots on the clinical side

Aiforia’s H2 revenue surpassed our expectations, and the earnings were in line with our estimate.

Aiforia Technologies
Aiforia, Webcast, H2, 2025
Webcast3/6/2026, 8:00 AM

Aiforia, Webcast, H2, 2025

Aiforia Technologies
Regulatory press release3/6/2026, 7:00 AM

Aiforia Technologies Plc’s Financial Statements Bulletin for January–December 2025 (unaudited): Clinical sector revenue increased 68% in 2025, driven by portfolio expansion and commercial execution

Aiforia Technologies
Forum discussions
Keep these coming, more and more, although they are unfortunately slow to monetize. The wait is long, especially since all parties must proceed slowly through pilots for each cancer type separately before this becomes mainstream. *> Aiforia selected as AI partner for PROSTIA project...
7 hours ago
by Opa
27
Well, what do you know, it hit the mark! The hint was this funding, where a project by a Dana-Farber researcher matched a bit too precisely what Aiforia’s earlier press release opened up about. MLSC – 22 Dec 25 Healey-Driscoll Administration Announces More Than $20 Million in Life...
4/14/2026, 4:27 PM
by Puutaheinää
19
aiforia.com Aiforia Announces Collaboration on Bladder Cancer Research with Renowned... Aiforia and Dana-Farber Cancer Institute partner to advance bladder cancer treatment using Aiforia® Create-built AI solution.
4/14/2026, 4:18 PM
by Salvelinus
16
There were also inklings of this on December 25th In itself, it’s quite a niche area: predicting treatment outcomes for metastatic bladder cancer. They combine Aiforia’s tools and expertise in histology with spatial transcriptomics, which is a map of which genes are expressed in ...
yesterday
by Vino Pino
13
The minutes of the General Meeting can be found on Aiforia’s website (investors/AGM2026) It was a close call; 65% voted in favor, while 2/3 (66.67%) was required. The EGM indeed has the same proposal, so if the opposing shareholders had an alternative financing plan, the board hasn...
yesterday
by Puutaheinää
9
An explanation has now been provided for the blocking of the share issue at the Annual General Meeting: “The shareholder who requested the Extraordinary General Meeting has stated that the voting result was caused by technical and administrative difficulties encountered by several...
yesterday
by Vino Pino
8
aiforia.com Mayo Clinic study: AI is enhancing Ki-67 scoring in breast cancer pathology Explore manual Ki-67 scoring challenges and Aiforia® Create-built AI model’s excellent performance in a Mayo Clinic study of 1,877 breast cancer cases. The company’s own publication from the breast...
4/13/2026, 11:40 AM
by Salvelinus
7
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.